Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report

J Allergy Clin Immunol. 2006 Jun;117(6):1292-302. doi: 10.1016/j.jaci.2006.02.042. Epub 2006 May 3.


Hypereosinophilic syndromes are a heterogeneous group of uncommon disorders characterized by the presence of marked peripheral blood eosinophilia, tissue eosinophilia, or both, resulting in a wide variety of clinical manifestations. Although corticosteroids are the first-line therapy for many of these disorders, approaches to the treatment of patients who do not tolerate or are unresponsive to corticosteroids are poorly standardized. A multidisciplinary group of 37 clinicians and scientists participated in a workshop held in May 2005 in Bern, Switzerland to discuss current and future approaches to therapy for 3 eosinophil-mediated disorders: hypereosinophilic syndrome, Churg-Strauss syndrome, and eosinophil-associated gastrointestinal disease. The goal of the workshop was to summarize available data regarding treatment of these disorders to identify the most promising therapies and approaches for further study. There was consensus among all of the participants that the identification of markers of disease progression to assess treatment responses is a research priority for all 3 disorders. Furthermore, the need for newer therapeutic strategies and novel drugs, as well as multicenter trials to assess all treatment modalities, was emphasized.

Publication types

  • Consensus Development Conference
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Disease Progression
  • Humans
  • Hypereosinophilic Syndrome / diet therapy
  • Hypereosinophilic Syndrome / drug therapy
  • Hypereosinophilic Syndrome / immunology
  • Hypereosinophilic Syndrome / therapy*


  • Biomarkers